Cattlemen to fashion designers, Hopper followers flock to Radiopharm – The Australian Financial Review


It won’t just be the famous faces hoping Radiopharm does well on Thursday.

The listing is an important one for joint lead managers Bell Potter and Baker Young.

It’s been a tough market for local biotech and pharmaceutical companies of late, with raisings getting away, but stocks typically trading down in the months afterwards.

Imugene has been an exception to this, up 73 per cent since it raised around $95 million in late July.